Cargando…

Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe

BACKGROUND: Prisoners have a high prevalence of hepatitis C virus (HCV) infection but may find it difficult to access healthcare services. This may be related to risk behaviour including history of injecting drugs and marginalisation related to problem drug use/ opioid use disorder (OUD). Direct-act...

Descripción completa

Detalles Bibliográficos
Autores principales: Stöver, H., Meroueh, F., Marco, A., Keppler, K., Saiz de la Hoya, P., Littlewood, R., Wright, N., Nava, F., Alam, F., Walcher, S., Somaini, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323720/
https://www.ncbi.nlm.nih.gov/pubmed/30621658
http://dx.doi.org/10.1186/s12889-018-6357-x
_version_ 1783385821782474752
author Stöver, H.
Meroueh, F.
Marco, A.
Keppler, K.
Saiz de la Hoya, P.
Littlewood, R.
Wright, N.
Nava, F.
Alam, F.
Walcher, S.
Somaini, L.
author_facet Stöver, H.
Meroueh, F.
Marco, A.
Keppler, K.
Saiz de la Hoya, P.
Littlewood, R.
Wright, N.
Nava, F.
Alam, F.
Walcher, S.
Somaini, L.
author_sort Stöver, H.
collection PubMed
description BACKGROUND: Prisoners have a high prevalence of hepatitis C virus (HCV) infection but may find it difficult to access healthcare services. This may be related to risk behaviour including history of injecting drugs and marginalisation related to problem drug use/ opioid use disorder (OUD). Direct-acting antiviral products with superior efficacy and safety compared to interferon-based regimens offer HCV cure. Many citizens in Europe have been treated, although few received therapy in prisons. METHODS: Analysis of prisoner HCV treatment need and policy determinants of clinical practice was completed for 5 EU countries. Evidence was collected from national statistical sources and peer-reviewed publications to describe prison populations and HCV prevalence, to map national prison/ HCV health policy or guidance. A consensus of important principles for prisoner HCV care was developed. RESULTS: Data from published sources describing prisoner HCV prevalence is limited. Prisoner population requiring HCV treatment is not known; estimated numbers based on analysis of evidence: England and Wales, 9000, France, 8000, Spain, 6000, Italy, 6000, Germany, 6000. Treatment access: national law defines right to equivalent care in all countries implying access to HCV therapy in prison similar to community; useful prisoner HCV guidance facilitating treatment decisions present in: 4 of 5 national/ regional HCV policy documents, 4 of 5 national prison healthcare policies. Four of five had practical prison HCV clinical guidelines. Despite existence of policy, implementation of guidance, and so HCV treatment, is suboptimal in many locations. CONCLUSIONS: Prison is an important location to detect, address and treat HCV infection in people who may be underserved for healthcare and find it difficult to navigate community treatment pathways. This is often related to problems with OUD and resulting social inequity. HCV management in prisons must be improved. Policy and clinical practice guidance must be set to promote treatment, and practical steps to make treatment easy should be followed including education to promote engagement, set-up of optimal screening and work up processes with modern tools to reduce time needed/ achieve efficiency; programs to make it easier to get specialists’ input include remote working and nurse-led services.
format Online
Article
Text
id pubmed-6323720
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63237202019-01-10 Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe Stöver, H. Meroueh, F. Marco, A. Keppler, K. Saiz de la Hoya, P. Littlewood, R. Wright, N. Nava, F. Alam, F. Walcher, S. Somaini, L. BMC Public Health Research Article BACKGROUND: Prisoners have a high prevalence of hepatitis C virus (HCV) infection but may find it difficult to access healthcare services. This may be related to risk behaviour including history of injecting drugs and marginalisation related to problem drug use/ opioid use disorder (OUD). Direct-acting antiviral products with superior efficacy and safety compared to interferon-based regimens offer HCV cure. Many citizens in Europe have been treated, although few received therapy in prisons. METHODS: Analysis of prisoner HCV treatment need and policy determinants of clinical practice was completed for 5 EU countries. Evidence was collected from national statistical sources and peer-reviewed publications to describe prison populations and HCV prevalence, to map national prison/ HCV health policy or guidance. A consensus of important principles for prisoner HCV care was developed. RESULTS: Data from published sources describing prisoner HCV prevalence is limited. Prisoner population requiring HCV treatment is not known; estimated numbers based on analysis of evidence: England and Wales, 9000, France, 8000, Spain, 6000, Italy, 6000, Germany, 6000. Treatment access: national law defines right to equivalent care in all countries implying access to HCV therapy in prison similar to community; useful prisoner HCV guidance facilitating treatment decisions present in: 4 of 5 national/ regional HCV policy documents, 4 of 5 national prison healthcare policies. Four of five had practical prison HCV clinical guidelines. Despite existence of policy, implementation of guidance, and so HCV treatment, is suboptimal in many locations. CONCLUSIONS: Prison is an important location to detect, address and treat HCV infection in people who may be underserved for healthcare and find it difficult to navigate community treatment pathways. This is often related to problems with OUD and resulting social inequity. HCV management in prisons must be improved. Policy and clinical practice guidance must be set to promote treatment, and practical steps to make treatment easy should be followed including education to promote engagement, set-up of optimal screening and work up processes with modern tools to reduce time needed/ achieve efficiency; programs to make it easier to get specialists’ input include remote working and nurse-led services. BioMed Central 2019-01-08 /pmc/articles/PMC6323720/ /pubmed/30621658 http://dx.doi.org/10.1186/s12889-018-6357-x Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Stöver, H.
Meroueh, F.
Marco, A.
Keppler, K.
Saiz de la Hoya, P.
Littlewood, R.
Wright, N.
Nava, F.
Alam, F.
Walcher, S.
Somaini, L.
Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe
title Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe
title_full Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe
title_fullStr Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe
title_full_unstemmed Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe
title_short Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe
title_sort offering hcv treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in europe
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323720/
https://www.ncbi.nlm.nih.gov/pubmed/30621658
http://dx.doi.org/10.1186/s12889-018-6357-x
work_keys_str_mv AT stoverh offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT merouehf offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT marcoa offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT kepplerk offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT saizdelahoyap offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT littlewoodr offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT wrightn offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT navaf offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT alamf offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT walchers offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope
AT somainil offeringhcvtreatmenttoprisonersisanimportantopportunitykeyprinciplesbasedonpolicyandpracticeassessmentineurope